Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
516.69
-2.95 (-0.57%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
8
Next >
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion
January 18, 2024
Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, and market insights.
Via
Benzinga
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
January 15, 2024
These five biotech companies could have a lot of room to run.
Via
The Motley Fool
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
December 22, 2023
Despite a Wednesday tumble, the major indexes are right at 2023 highs.
Via
Investor's Business Daily
Argenx's Autoimmune Trial Stumble: Analysts Cut Price Targets, Warn of Risky Outcomes
December 21, 2023
Wednesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus...
Via
Benzinga
Why Is Argenx (ARGX) Stock Down 25% Today?
December 20, 2023
Following a late-stage clinical disappointment, Argenx has been forced back to the drawing board, thus cratering ARGX stock.
Via
InvestorPlace
Argenx Dives On Autoimmune Therapy Failure
December 20, 2023
A treatment for a skin-blistering condition failed to beat a placebo.
Via
Investor's Business Daily
Stifel Maintains Buy Rating for argenx: Here's What You Need To Know
December 18, 2023
Via
Benzinga
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
December 21, 2023
Immunovant reversed its fortunes Thursday following an Argenx-tied selloff Wednesday.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 21, 2023
Via
Benzinga
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
December 21, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
December 20, 2023
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results.
Via
Benzinga
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today
December 01, 2023
Via
Benzinga
Analyst Ratings for argenx
November 29, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 20, 2023
Via
Benzinga
Why Is European Drugmaker Argenx Stock Sinking Today?
December 20, 2023
Argenx SE (NASDAQ: ARGX) shares plunged after the company released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in...
Via
Benzinga
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
December 20, 2023
Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 20, 2023
Via
Benzinga
These 2 Stocks Are Falling in a Fading Rally
November 28, 2023
It's been a good month, but the stock market's looking tired.
Via
The Motley Fool
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
November 15, 2023
Via
Benzinga
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
December 20, 2023
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
December 01, 2023
Software earnings were strong, while the Fed is shifting toward rate cuts.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Morgan Stanley Maintains Overweight Rating for argenx: Here's What You Need To Know
November 30, 2023
Via
Benzinga
Micron To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday
November 29, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 28, 2023
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.
Via
Benzinga
Why Is Dutch Pharma Argenx Trading Lower Today?
November 28, 2023
Tuesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADVANCE-SC study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with primary immune thrombocytopenia...
Via
Benzinga
Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug
November 28, 2023
The company was hoping its drug would make a difference for patients with a rare blood disorder.
Via
Investor's Business Daily
Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
November 28, 2023
Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults...
Via
Benzinga
Exposures
Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
November 28, 2023
It's time to dive into the biggest pre-market stock movers for Tuesday morning with all of the latest news you need to know today!
Via
InvestorPlace
Zscaler Posts Q1 Results, Joins argenx, Cool Company And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
November 28, 2023
U.S. stock futures traded mixed this morning, with the Dow Jones futures gaining around 15 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
November 22, 2023
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.